Kura Oncology to Report Fourth Quarter and Full Year 2020 Financial Results

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced it will report its fourth quarter and full year 2020 financial results on February 24, 2021, before U.S. markets open. Management will host a conference call at 8:00 a.m. ET to discuss these results and provide a corporate update. The company is focused on developing precision medicines for cancer treatment, with two key candidates: tipifarnib for HRAS mutant head and neck cancer, and KO-539 for acute myeloid leukemia, currently in clinical trials. For details, visit their website.

Positive

• Kura's pipeline includes promising drug candidates with advanced clinical trials.
• Tipifarnib is currently in a registration-directed trial, indicating progress towards potential approval.

Negative

• None.

SAN DIEGO, Feb. 17, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2020 financial results before the open of U.S. financial markets on Wednesday, February 24, 2021. Kura’s management will host a webcast and conference call at 8:00 a.m. ET / 5:00 a.m. PT that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing (877) 516-3514 for domestic callers and (281) 973-6129 for international callers and entering the conference code: 8581798. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.kuraoncology.com.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of two wholly owned small molecule drug candidates that target cancer signaling pathways where there is a strong scientific and clinical rationale to improve outcomes by identifying those patients most likely to benefit from treatment. Kura’s most advanced drug candidate is tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor currently in a registration-directed trial (AIM-HN) in patients with recurrent or metastatic HRAS mutant head and neck squamous cell carcinoma. The Company’s pipeline is also highlighted by KO-539, a potent and selective menin inhibitor currently in a Phase 1/2A clinical trial (KOMET-001) in patients with relapsed/refractory acute myeloid leukemia. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When will Kura Oncology report its financial results for 2020?

Kura Oncology will report its fourth quarter and full year 2020 financial results on February 24, 2021.

What time is Kura Oncology's conference call scheduled for?

The conference call is scheduled for 8:00 a.m. ET on February 24, 2021.

What are the main drug candidates being developed by Kura Oncology?

Kura Oncology is developing tipifarnib for HRAS mutant head and neck cancer and KO-539 for acute myeloid leukemia.

Where can I access the live webcast of Kura Oncology's call?

The live webcast can be accessed from the investor relations section of Kura Oncology's website.